| Biotech Industry Overview |
| Global | Amount | Units | Year | Source |
| Public & Private Biotech Companies (US, Europe and Canada) | 4,361 | Companies | 2009 | E&Y |
| Public Biotech Companies | 622 | Companies | 2009 | E&Y |
| Biotech Revenues | 79.1 | Bil. US$ | 2009 | E&Y |
| Total Pharmaceutical Sales, Worldwide | 837.0 | Bil. US$ | 2009 | IMS |
| Total R&D Expenses, PhRMA Member Companies | 47.4 | Bil. US$ | 2009 | PhRMA |
| Total R&D Expenses, All Pharmaceutical Companies | 65.3 | Bil. US$ | 2009 | Burrill |
| U.S. |
| Public & Private Biotech Companies | 1,699 | Companies | 2009 | E&Y |
| Public Biotech Companies | 313 | Companies | 2009 | E&Y |
| Revenues | 56.6 | Bil. US$ | 2009 | E&Y |
| Area of Biotech Crops | 64.0 | Mil. Hectares | 2009 | ISAAA |
| Prescription Drug Sales, Domestic | 300.3 | Bil. US$ | 2009 | IMS |
| Number of FDA Approvals for New Drugs (NDAs) and Biologic License Applications (BLAs) | 97 | Approvals | 2009 | FDA |
| Number of Approvals for New Molecular Entities (NMEs) and BLAs | 25 | Approvals | 2009 | FDA |
| Patents Granted for "Multicellular Living Organisms & Unmodified Parts Thereof & Related Processes" | 946 | Patents | 2009 | USPTO |
| Medical Research Funding, NIH | 31.2 | Bil. US$ | 2009 | NIH |
| Total Requested Budget for Biological Science Research, U.S. (NSF) | 733.0 | Mil. US$ | 2010 | NSF |
| Mean Annual Salary for Biochemists & Biophysicists | 88,550 | US$ | May-09 | BLS |
| Average Cost of Developing a Biologic Drug | 1.2 | Bil. US$ | 2005 | Tufts |
| PhRMA1 Member Statistics, U.S. |
| Pharmaceutical Sales, Domestic | 183.0 | Bil. US$ | 2009 | PhRMA |
| % Generic (by volume) | 64.0 | % | 2009 | PhRMA |
| Pharmaceutical Sales, Foreign2 | 103.4 | Bil. US$ | 2009 | PhRMA |
| Pharmaceutical R&D Spending, Domestic | 35.6 | Bil. US$ | 2009 | PhRMA |
| as a Percentage of Domestic Sales | 19.4 | % | 2009 | PhRMA |
| Share of R&D Spending by Function: |
| Prehuman/Preclinical | 28.8 | % | 2008 | PhRMA |
| Phase I | 7.1 | % | 2008 | PhRMA |
| Phase II | 10.5 | % | 2008 | PhRMA |
| Phase III | 23.5 | % | 2008 | PhRMA |
| Approval | 5.5 | % | 2008 | PhRMA |
| Phase IV | 12.9 | % | 2008 | PhRMA |
| Uncategorized | 0.5 | % | 2008 | PhRMA |
| 1 PhRMA = Pharmaceutical Research and Manufacturers Association, a group of leading pharmaceutical and biotechnology companies in the U.S. 2 Not including foreign divisions of foreign companies. |
| E&Y = Ernst & Young; IMS = IMS Health; Burrill = Burrill & Company; ISAAA = International Service for the Acquisition of Agri-Biotech Applications; Tufts = Tufts University Center for the Study of Drug Development; FDA = U.S. Food & Drug Administration; USPTO = U.S. Patent & Trademark Office; NIH = U.S. National Institutes of Health; NSF = U.S. National Science Foundation; BLS = U.S. Bureau of Labor Statistics |
| | | | | |
| Source: Plunkett Research, Ltd. Copyright © 2010, All Rights Reserved |
| www.plunkettresearch.com |